GM-CSF Protein

Catalog No. ABIN7318085

This Recombinant GM-CSF protein is expressed in HEK-293 Cells.

Quick Overview for GM-CSF Protein (ABIN7318085)

Target: GM-CSF (CSF2) (Colony Stimulating Factor 2 (Granulocyte-Macrophage) (CSF2))

Protein Type: Recombinant

Biological Activity: Active

Origin: Human

Source: HEK-293 Cells

Application: Cell Culture (CC)

Purity: > 90 % as determined by reducing SDS-PAGE.

Product Details

Purpose: Recombinant Human GM-CSF/CSF2 Protein (HEK293 Cells)

Sequence: Met 1-Glu144

Characteristics: A DNA sequence encoding human GMCSF (NP_000749.2) (Met1-Glu144) was expressed.

Sterility: 0.2 μm filtered

Endotoxin Level: < 1.0 EU per μg of the protein as determined by the LAL method.

Biological Activity Comment: Measured in a cell proliferation assay using TF-1 human erythroleukemic cells. The ED₅₀ for this effect is typically 0.1-0.6 ng/ml.

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Buffer: Lyophilized from sterile PBS, pH 7.4.
Normally 5 % - 8 % trehalose, mannitol and 0.01 % Tween 80 are added as protectants before lyophilization.

Storage: 4 °C,-20 °C,-80 °C

Storage Comment: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

Expiry Date: 12 months

Target Details

Target: GM-CSF (CSF2) (Colony Stimulating Factor 2 (Granulocyte-Macrophage) (CSF2))

Alternative Name: GM-CSF/CSF2

Background: CSF,CSF2,Colony-Stimulating Factor,GM-CSF,GMCSF,Granulocyte-Macrophage Colony-Stimulating Factor,Molgramostin,Sargramostim,Granulocyte-macrophage colony-stimulating factor (GM-CSF) is one of an array of cytokines with pivotal roles in embryo implantation and subsequent development. Several cell lineages in the reproductive tract and gestational tissues synthesise GM-CSF under direction by ovarian steroid hormones and signalling agents originating in male seminal fluid and the conceptus. The pre-implantation embryo, invading placental trophoblast cells and the abundant populations of leukocytes controlling maternal immune tolerance are all subject to GM-CSF regulation. GM-CSF stimulates the differentiation of hematopoietic progenitors to monocytes and neutrophils, and reduces the risk for febrile neutropenia in cancer patients. GM-CSF also has been shown to induce the differentiation of myeloid dendritic cells (DCs) that promote the development of T-helper type 1 immune responses in cognate T cells. As a part of the immune/inflammatory cascade, GM-CSF promotes Th1 biased immune response, angiogenesis, allergic inflammation, and the development of autoimmunity, and thus worthy of consideration for therapeutic target. GM-CSF has been utilized in the clinical management of multiple disease processes. Most recently, GM-CSF has been incorporated into the treatment of malignancies as a sole therapy, as well as a vaccine adjuvant. While the benefits of GM-CSF in this arena have been promising, recent reports have suggested the potential for GM-CSF to induce immune suppression and, thus, negatively impact outcomes in the management of cancer patients.

Molecular Weight:

Calculated MW: 14.5 kDa

Observed MW: 23.8 kDa

Gene ID: 1437

NCBI Accession: NP_000749

UniProt: P04141

Pathways: JAK-STAT Signaling, Cellular Response to Molecule of Bacterial Origin